Medical/Pharmaceuticals
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-02 08:00
6176
CAMH study confirms ongoing brain inflammation associated with long COVID
Researchers using advanced brain imaging are first to find increase in protein marker of inflammation in illness affecting 200 million globally TORONTO, June 2, 2023 /PRNewswire/ -- A new CAMH study published in the journalJAMA Psychiatry found elevated levels of inflammation in the brain of pa...
2023-06-02 04:07
2797
EVERSANA Forms Strategic Alliance with China Resource Pharmaceutical Commercial Group to Bring New Novel Treatments to Patients Globally
BEIJING, June 2, 2023 /PRNewswire/ -- EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today announced that it has established a strategic alliance with the China Resources Pharmaceutical Commercial Group, a leading pharmaceutical distribution ent...
2023-06-02 00:10
2970
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...
2023-06-02 00:06
7047
GenEros to Present Promising Results of GEC255 Phase I Clinical Trial for Advanced NSCLC Patients with KRAS G12C Mutation
HANGZHOU, China, June 1, 2023 /PRNewswire/ -- GenEros Biopharma Ltd. ("GenEros" or "the Company"), a biopharmaceutical company dedicated to discovering, developing, and commercializing novel medicines for diseases with unmet medical needs, will unveil the preliminary data from the phase I clinica...
2023-06-01 22:15
2478
AtomVie Global Radiopharma raises over $90M to Complete its New Facility Buildout
HAMILTON, ON, June 1, 2023 /PRNewswire/ -- AtomVie Global Radiopharma Inc. (AtomVie), a global-leading CDMO for the GMP manufacturing and worldwide distribution of radiopharmaceuticals, today announced the closing of its Tranche 2 Series A financing led by its current investor, Avego Management, ...
2023-06-01 21:00
2033
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2023-06-01 20:30
2864
Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors
SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, and Eikon Therapeutics ("Eikon"), a biotechnology company that is adv...
2023-06-01 20:30
2345
BIORCHESTRA Invited to Present Update on Central Nervous System Lead Program (BMD-001) and IV-Formulated siRNA Data at BIO2023 International Conference
* Presentation:"Successfully Achieving Intravenous (IV)-formulated RNA Delivery to the Brain, Evidence of Efficacy" scheduled for June 08, 2023, 12:00 p.m. ET, Room 104A * Pioneering IV-formulated inert drug delivery platform targeting neurodegenerative diseases * Lead program (BMD-001) adv...
2023-06-01 20:00
2239
Aravax doses first patient in Phase 2 peanut allergy clinical trials
MELBOURNE, Australia, June 1, 2023 /PRNewswire/ -- The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted under a U....
2023-06-01 20:00
1914
Seegene Obtains IVDR Certification for 30 Diagnostic Assays
* Seegene certifies diagnostic assays for digestive, respiratory, women's diseases, and human papillomavirus to meet IVDR requirements * New regulation sets improved standards to ensure higher level of quality, safety, and reliability SEOUL, South Korea, June 1, 2023 /PRNewswire/ -- Seegene I...
2023-06-01 19:00
2101
Xinhua Silk Road: Activity to promote TCM cultural exchanges and cooperation between China and Luxembourg completes success
BEIJING, June 1, 2023 /PRNewswire/ -- An activity to promote traditional
Chinese medicine (TCM) cultural exchanges and cooperation betweenChina and
Luxembourg held recently at the Luxembourg Embassy in China achieved a complete
success.
2023-06-01 17:37
2047
Xinhua Silk Road: Global co-op highlighted in tour of Chinese herbs firm to Indonesian embassy in China
BEIJING, June 1, 2023 /PRNewswire/ -- A tour to the Indonesian embassy in China
by representatives from Zhejiang Longevity Valley Botanical Co., Ltd. cast a
spot light on the rising importance of cooperation and communication in the era
of globalization.
2023-06-01 17:35
2329
Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe
VIENNA, June 1, 2023 /PRNewswire/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets includin...
2023-06-01 17:18
3407
WuXi Biologics to Increase Manufacturing Capacity in Germany
- In response to global clients' increasing demand for contract manufacturing services, WuXi Biologics is expanding its capacity for drug substance and drug product inGermany - The investment promotes the creation of additional high-skilled jobs - As part of WuXi Biologics' global manufacturi...
2023-06-01 16:49
3498
Mediso installs 100% cryogen-free 7T MRI at the University of Milano-Bicocca, Italy
BUDAPEST, Hungary, June 1, 2023 /PRNewswire/ -- Mediso
2023-06-01 16:00
2133
CRScube Expands Services in Europe with New Clinical Study Collaborations
SEOUL, South Korea, June 1, 2023 /PRNewswire/ -- CRScube, a leading provider of eClinical solutions, today announced its recent collaborations with two European companies. These new collaborations aim to expand the reach of CRScube's innovative eClinical solutions in the European clinical trial ...
2023-06-01 16:00
2488
New Genea Fertility Clinic to Open in North Melbourne
MELBOURNE, Australia , June 1, 2023 /PRNewswire/ -- Genea Fertility is pleased
to announce the expansion of its services inVictoria with the opening of a new
clinic inNorth Melbourne.
2023-06-01 15:58
3000
GenesisCare Files for Voluntary Reorganisation to Advance Business Transformation
Company to Obtain US$200 Million in New Financing to Support Ordinary Course Business Operations Globally All GenesisCare Businesses Show Strong Momentum and Growth Potential Company to Pursue Separation of U.S. Business While U.S. Management Implements Turnaround Strategy SYDNEY, June 1, 2023...
2023-06-01 14:09
2456
Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma
- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) ofAustralia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in triple class refractory R/R MM. - This inclusion b...
2023-06-01 10:09
3237
Week's Top Stories
Most Reposted
Agoda releases generative AI film to capture the joy of travel
[Picked up by 349 media titles]
2024-12-10 10:00
Mastercard Economics Institute: APAC growth expected to hold steady in 2025; global policy resets may see shift in gears
[Picked up by 313 media titles]
2024-12-10 09:00Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
[Picked up by 306 media titles]
2024-12-09 10:00
CCTV+: Yuhang Journey ǀ Follow Olivier to Explore Ancient Liangzhu and Savor Jingshan Tea
[Picked up by 283 media titles]
2024-12-08 20:076th HIIFF Closes with Golden Coconut Award Ceremony
[Picked up by 282 media titles]
2024-12-11 22:19
Most Read
Agoda releases generative AI film to capture the joy of travel
2024-12-10 10:00
3700
Blokees' Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
2024-12-08 00:23
3560
Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
2024-12-09 10:00
3476